礼来将以24亿美元收购Orna，加强自体免疫领域布局

Core Viewpoint - Eli Lilly announced the acquisition of biotechnology company Orna Therapeutics for up to $2.4 billion in cash, focusing on the development of ORN-252, a candidate drug aimed at treating B cell-driven autoimmune diseases currently in early-stage development [1] Group 1 - Eli Lilly is acquiring Orna Therapeutics for a total cash consideration of up to $2.4 billion [1] - Orna Therapeutics' main candidate drug, ORN-252, targets B cell-driven autoimmune diseases [1] - The drug ORN-252 is currently in the early stages of development [1]